{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T02:16:40Z","timestamp":1784945800500,"version":"3.55.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The objective of this study was to expand real-life data on cefiderocol efficacy to treat multidrug-resistant Acinetobacter baumannii infections.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a retrospective monocentric study including patients hospitalized (&amp;gt;24 hours) at Policlinico Tor Vergata, Rome, Italy, between May 1, 2021, and September 1, 2022, treated with cefiderocol (&amp;gt;48 hours). The primary objective was early clinical improvement at 48\u201372 hours from cefiderocol start; secondary objectives were clinical success (composite outcome of infection resolution and 14-day survival), breakthrough infection, overall 30-day mortality, and cefiderocol-related adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Eleven patients were enrolled; 91% males (10\/11), with a median age (interquartile range [IQR]) of 69 (59\u201371) years, 91% had \u22651 comorbidity, and 72.7% (8\/11) were hospitalized in internal medicine wards. Six patients with bloodstream infection (54.5%; 4 primary, 2 central line\u2013associated), 2 with pneumonia (18.2%), 2 with urinary tract infections (18.2%), and 1 with intra-abdominal infection (9.1%) were treated. Four patients (36.3%) presented with septic shock at cefiderocol start. Cefiderocol was used as monotherapy in 3\/11 patients (27.3%), was combined with colistin in all the other 8 cases, and was used in triple combination with tigecycline in 2 patients. The median duration of treatment (IQR) was 12 (10\u201314) days. Early clinical improvement was documented in 8\/11 patients (72.7%), clinical success in 8\/11 patients (72.7%). Overall 30-day mortality was 27.3% (3\/11), with death occurring a median (IQR) of 19 (17.5\u201320.5) days after the start of therapy. No cefiderocol-related adverse events were documented.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Cefiderocol seems to be a safe and effective option for multidrug-resistant Acinetobacter baumannii infections.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofad627","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T18:28:51Z","timestamp":1703010531000},"source":"Crossref","is-referenced-by-count":7,"title":["Real-life Data on Cefiderocol Efficacy and Safety to Treat Multidrug-Resistant <i>Acinetobacter baumannii<\/i> Infections"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7462-169X","authenticated-orcid":false,"given":"Laura","family":"Campogiani","sequence":"first","affiliation":[{"name":"Infectious Diseases Clinic, Policlinico Tor Vergata , Rome , Italy"},{"name":"Department of Systems Medicine, Tor Vergata University , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4978-7057","authenticated-orcid":false,"given":"Angela Maria Antonia","family":"Crea","sequence":"additional","affiliation":[{"name":"Infectious Diseases Clinic, Policlinico Tor Vergata , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Letizia","family":"Minardi","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, Tor Vergata University , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1597-3393","authenticated-orcid":false,"given":"Lorenzo","family":"Ansaldo","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, Tor Vergata University , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Coppola","sequence":"additional","affiliation":[{"name":"Infectious Diseases Clinic, Policlinico Tor Vergata , Rome , Italy"},{"name":"Department of Systems Medicine, Tor Vergata University , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6372-5434","authenticated-orcid":false,"given":"Mirko","family":"Compagno","sequence":"additional","affiliation":[{"name":"Infectious Diseases Clinic, Policlinico Tor Vergata , Rome , Italy"},{"name":"Department of Systems Medicine, Tor Vergata University , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9563-0964","authenticated-orcid":false,"given":"Pietro","family":"Vitale","sequence":"additional","affiliation":[{"name":"Infectious Diseases Clinic, Policlinico Tor Vergata , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Spalliera","sequence":"additional","affiliation":[{"name":"Infectious Diseases Clinic, Policlinico Tor Vergata , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6561-5298","authenticated-orcid":false,"given":"Vincenzo","family":"Malagnino","sequence":"additional","affiliation":[{"name":"Infectious Diseases Clinic, Policlinico Tor Vergata , Rome , Italy"},{"name":"Department of Systems Medicine, Tor Vergata University , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0785-9120","authenticated-orcid":false,"given":"Elisabetta","family":"Teti","sequence":"additional","affiliation":[{"name":"Infectious Diseases Clinic, Policlinico Tor Vergata , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"D\u2019agostini","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Microbiology, Policlinico Tor Vergata , Rome , Italy"},{"name":"Department of Experimental Medicine, Tor Vergata University , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Pennacchiotti","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy, Policlinico Tor Vergata , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide Natale","family":"Abate","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy, Policlinico Tor Vergata , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Celeste","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy, Policlinico Tor Vergata , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3205-9758","authenticated-orcid":false,"given":"Massimo","family":"Andreoni","sequence":"additional","affiliation":[{"name":"Infectious Diseases Clinic, Policlinico Tor Vergata , Rome , Italy"},{"name":"Department of Systems Medicine, Tor Vergata University , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6938-8627","authenticated-orcid":false,"given":"Marco","family":"Iannetta","sequence":"additional","affiliation":[{"name":"Infectious Diseases Clinic, Policlinico Tor Vergata , Rome , Italy"},{"name":"Department of Systems Medicine, Tor Vergata University , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1452-0333","authenticated-orcid":false,"given":"Loredana","family":"Sarmati","sequence":"additional","affiliation":[{"name":"Infectious Diseases Clinic, Policlinico Tor Vergata , Rome , Italy"},{"name":"Department of Systems Medicine, Tor Vergata University , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,12,21]]},"reference":[{"key":"2023122813153960900_ofad627-B1","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European Society of Intensive Care Medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2023122813153960900_ofad627-B2","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious Diseases Society of America guidance on the treatment of AmpC \u03b2-lactamase-producing enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections","volume":"74","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2023122813153960900_ofad627-B3","author":"Surveillance Atlas of Infectious Diseases"},{"key":"2023122813153960900_ofad627-B4","article-title":"FDA approves new antibacterial drug to treat complicated urinary tract infections as part of ongoing efforts to address antimicrobial resistance","author":"Food and Drug Administration","year":"2020"},{"key":"2023122813153960900_ofad627-B5","article-title":"Fetcroja","author":"European Medicines Agency","year":"2020"},{"key":"2023122813153960900_ofad627-B6","doi-asserted-by":"crossref","first-page":"S538","DOI":"10.1093\/cid\/ciz826","article-title":"Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin","volume":"69","author":"Sato","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023122813153960900_ofad627-B7","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2023122813153960900_ofad627-B8","doi-asserted-by":"crossref","first-page":"e0214221","DOI":"10.1128\/aac.02142-21","article-title":"Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii","volume":"66","author":"Falcone","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2023122813153960900_ofad627-B9","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1093\/cid\/ciaa1410","article-title":"Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant gram-negative infections in intensive care unit patients","volume":"72","author":"Falcone","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023122813153960900_ofad627-B10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/antibiotics11010003","article-title":"Cefiderocol for severe carbapenem-resistant A. baumannii pneumonia: towards the comprehension of its place in therapy","volume":"11","author":"Rando","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2023122813153960900_ofad627-B11","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/antibiotics10121475","article-title":"Place in therapy of the newly available armamentarium for multi-drug-resistant gram-negative pathogens: proposal of a prescription algorithm","volume":"10","author":"Volpicelli","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2023122813153960900_ofad627-B12","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s15010-022-01933-5","article-title":"Case series of cefiderocol for salvage therapy in carbapenem-resistant gram-negative infections","volume":"51","author":"Gavaghan","year":"2023","journal-title":"Infection"},{"key":"2023122813153960900_ofad627-B13","doi-asserted-by":"crossref","first-page":"dlab174","DOI":"10.1093\/jacamr\/dlab174","article-title":"Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study","volume":"3","author":"Pascale","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"2023122813153960900_ofad627-B14","doi-asserted-by":"crossref","first-page":"R38","DOI":"10.1186\/cc7751","article-title":"Procalcitonin kinetics within the first days of sepsis: relationship with the appropriateness of antibiotic therapy and the outcome","volume":"13","author":"Charles","year":"2009","journal-title":"Crit Care"},{"key":"2023122813153960900_ofad627-B15","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1473-3099(16)00053-0","article-title":"Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial","volume":"16","author":"de Jong","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2023122813153960900_ofad627-B16","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1001\/jama.2020.6348","article-title":"Effect of C-reactive protein\u2013guided antibiotic treatment duration, 7-day treatment, or 14-day treatment on 30-day clinical failure rate in patients with uncomplicated gram-negative bacteremia","volume":"323","author":"von Dach","year":"2020","journal-title":"JAMA"},{"key":"2023122813153960900_ofad627-B17","author":"Centers for Disease Control and Prevention"},{"key":"2023122813153960900_ofad627-B18","article-title":"Annex I: summary of product characteristics","author":"European Medicines Agency"},{"key":"2023122813153960900_ofad627-B19","doi-asserted-by":"crossref","first-page":"e00059","DOI":"10.1128\/AAC.00059-20","article-title":"Case commentary: the need for cefiderocol is clear, but are the supporting clinical data?","volume":"64","author":"Shields","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2023122813153960900_ofad627-B20","doi-asserted-by":"crossref","first-page":"447.e1","DOI":"10.1016\/j.cmi.2021.07.018","article-title":"In vitro activity of the novel siderophore cephalosporin, cefiderocol, in gram-negative pathogens in Europe by site of infection","volume":"28","author":"Candel","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2023122813153960900_ofad627-B21","doi-asserted-by":"crossref","first-page":"e01968","DOI":"10.1128\/AAC.01968-17","article-title":"In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of gram-negative bacilli collected worldwide in 2014 to 2016","volume":"62","author":"Hackel","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2023122813153960900_ofad627-B22","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jgar.2021.04.019","article-title":"In vitro activity of cefiderocol and comparators against isolates of gram-negative pathogens from a range of infection sources: SIDERO-WT-2014\u20132018 studies in Italy","volume":"25","author":"Stracquadanio","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"2023122813153960900_ofad627-B23","doi-asserted-by":"crossref","first-page":"e01437","DOI":"10.1128\/AAC.01437-20","article-title":"Population pharmacokinetic and pharmacokinetic\/pharmacodynamic analyses of cefiderocol, a parenteral siderophore cephalosporin, in patients with pneumonia, bloodstream infection\/sepsis, or complicated urinary tract infection","volume":"65","author":"Kawaguchi","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2023122813153960900_ofad627-B24","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1093\/jac\/dkab280","article-title":"Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia","volume":"76","author":"Katsube","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2023122813153960900_ofad627-B25","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jgar.2021.10.014","article-title":"A descriptive case series of pharmacokinetic\/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant Acinetobacter baumannii bloodstream infection and\/or ventilator-associated pneumonia treated with cefiderocol","volume":"27","author":"Gatti","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"2023122813153960900_ofad627-B26","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(21)00194-8","article-title":"Widespread cefiderocol heteroresistance in carbapenem-resistant gram-negative pathogens","volume":"21","author":"Choby","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2023122813153960900_ofad627-B27","doi-asserted-by":"crossref","first-page":"e648","DOI":"10.1016\/S2666-5247(21)00271-8","article-title":"Does cefiderocol heteroresistance explain the discrepancy between the APEKS-NP and CREDIBLE-CR clinical trial results?","volume":"2","author":"Choby","year":"2021","journal-title":"Lancet Microbe"},{"key":"2023122813153960900_ofad627-B28","doi-asserted-by":"crossref","first-page":"e0234722","DOI":"10.1128\/spectrum.02347-22","article-title":"Acinetobacter baumannii and cefiderocol, between cidality and adaptability","volume":"10","author":"Stracquadanio","year":"2022","journal-title":"Microbiol Spectr"},{"key":"2023122813153960900_ofad627-B29","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1128\/AAC.00103-06","article-title":"Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii","volume":"50","author":"Li","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2023122813153960900_ofad627-B30","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/jac\/dki115","article-title":"Heteroresistance to carbapenems in Acinetobacter baumannii","volume":"55","author":"Pournaras","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"2023122813153960900_ofad627-B31","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s10096-022-04503-7","article-title":"In vitro and in vivo efficacy of cefiderocol plus tigecycline, colistin, or meropenem against carbapenem-resistant Acinetobacter baumannii","volume":"41","author":"Ni","year":"2022","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2023122813153960900_ofad627-B32","doi-asserted-by":"crossref","first-page":"e0264620","DOI":"10.1128\/AAC.02646-20","article-title":"In vitro antibacterial activity of cefiderocol against multidrug-resistant Acinetobacter baumannii","volume":"65","author":"Abdul-Mutakabbir","year":"2021","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofad627\/54737044\/ofad627.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/12\/ofad627\/54914393\/ofad627.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/12\/ofad627\/54914393\/ofad627.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T13:15:59Z","timestamp":1703769359000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofad627\/7486990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofad627","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12]]},"published":{"date-parts":[[2023,12,1]]},"article-number":"ofad627"}}